vs
Side-by-side financial comparison of INVESTORS TITLE CO (ITIC) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $69.5M, roughly 1.0× INVESTORS TITLE CO). On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -1.6%). INVESTORS TITLE CO produced more free cash flow last quarter ($25.4M vs $-84.7M).
The Real Estate Title Insurance Company of Philadelphia was the world's first title insurance company.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
ITIC vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $69.5M | $70.6M |
| Net Profit | — | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 13.8% | -56.7% |
| Net Margin | — | -49.0% |
| Revenue YoY | -1.6% | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $3.97 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $69.5M | — | ||
| Q3 25 | $73.0M | $70.6M | ||
| Q2 25 | $73.6M | — | ||
| Q1 25 | $56.6M | — | ||
| Q4 24 | $70.6M | — | ||
| Q3 24 | $68.8M | — | ||
| Q2 24 | $65.4M | — | ||
| Q1 24 | $53.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | $12.2M | $-34.6M | ||
| Q2 25 | $12.3M | — | ||
| Q1 25 | $3.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.3M | — | ||
| Q2 24 | $8.9M | — | ||
| Q1 24 | $4.5M | — |
| Q4 25 | 13.8% | — | ||
| Q3 25 | 20.7% | -56.7% | ||
| Q2 25 | 21.5% | — | ||
| Q1 25 | 7.2% | — | ||
| Q4 24 | 15.3% | — | ||
| Q3 24 | 16.8% | — | ||
| Q2 24 | 17.2% | — | ||
| Q1 24 | 10.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 16.7% | -49.0% | ||
| Q2 25 | 16.7% | — | ||
| Q1 25 | 5.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 13.5% | — | ||
| Q2 24 | 13.6% | — | ||
| Q1 24 | 8.5% | — |
| Q4 25 | $3.97 | — | ||
| Q3 25 | $6.45 | — | ||
| Q2 25 | $6.48 | — | ||
| Q1 25 | $1.67 | — | ||
| Q4 24 | $4.41 | — | ||
| Q3 24 | $4.92 | — | ||
| Q2 24 | $4.70 | — | ||
| Q1 24 | $2.40 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.6M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $268.3M | $503.0M |
| Total Assets | $363.1M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.6M | — | ||
| Q3 25 | $110.8M | $490.9M | ||
| Q2 25 | $90.1M | — | ||
| Q1 25 | $81.7M | — | ||
| Q4 24 | $83.8M | — | ||
| Q3 24 | $112.9M | — | ||
| Q2 24 | $111.2M | — | ||
| Q1 24 | $135.0M | — |
| Q4 25 | $268.3M | — | ||
| Q3 25 | $278.0M | $503.0M | ||
| Q2 25 | $266.2M | — | ||
| Q1 25 | $254.4M | — | ||
| Q4 24 | $251.8M | — | ||
| Q3 24 | $271.3M | — | ||
| Q2 24 | $261.8M | — | ||
| Q1 24 | $254.0M | — |
| Q4 25 | $363.1M | — | ||
| Q3 25 | $363.3M | $577.1M | ||
| Q2 25 | $345.8M | — | ||
| Q1 25 | $333.8M | — | ||
| Q4 24 | $333.6M | — | ||
| Q3 24 | $352.0M | — | ||
| Q2 24 | $340.3M | — | ||
| Q1 24 | $329.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.9M | $-84.6M |
| Free Cash FlowOCF − Capex | $25.4M | $-84.7M |
| FCF MarginFCF / Revenue | 36.5% | -120.1% |
| Capex IntensityCapex / Revenue | 8.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $47.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.9M | — | ||
| Q3 25 | $17.2M | $-84.6M | ||
| Q2 25 | $8.9M | — | ||
| Q1 25 | $-75.0K | — | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $7.8M | — | ||
| Q2 24 | $8.4M | — | ||
| Q1 24 | $1.4M | — |
| Q4 25 | $25.4M | — | ||
| Q3 25 | $15.8M | $-84.7M | ||
| Q2 25 | $7.3M | — | ||
| Q1 25 | $-1.4M | — | ||
| Q4 24 | $22.4M | — | ||
| Q3 24 | $6.1M | — | ||
| Q2 24 | $6.3M | — | ||
| Q1 24 | $-793.0K | — |
| Q4 25 | 36.5% | — | ||
| Q3 25 | 21.7% | -120.1% | ||
| Q2 25 | 9.9% | — | ||
| Q1 25 | -2.5% | — | ||
| Q4 24 | 31.7% | — | ||
| Q3 24 | 8.8% | — | ||
| Q2 24 | 9.7% | — | ||
| Q1 24 | -1.5% | — |
| Q4 25 | 8.0% | — | ||
| Q3 25 | 1.8% | 0.2% | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 10.5% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 4.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.40× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | -0.02× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.95× | — | ||
| Q1 24 | 0.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
